Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Clinical and experimental evidences suggests an immunomodulatory effect of sex hormones in
multiple sclerosis.
The role of oral estroprogestins in the pathogenesis and in the clinical course of the
disease is actually unknown.
The aim of the study is to investigate safety and tolerability of association of
estroprogestins in two different doses with interferon-beta 1a in patients with
relapsing-remitting multiple sclerosis.